-Detects directly total neutralizing antibodies to SARS-CoV-2 (not by correlation)
-Based on competitive immunodetection technology
-Reference method : PRNT and cPass ELISA assay
-Clinical sensitivity : 97.3%
-Clinical specificity : 100%

-Target nucleocapsid protein
-Result by visual reading
-5 Million tests sold to Public Health of France
-15-minute reaction time

-Detects SARS-CoV-2 E and RdRP genes
-70-minute run time
-LoD < 10 copies / reaction

-Semi-automated immunofluorescent assay
-Temperature stable sensitivity and specificity
-Semi-quantitative measurement
-12 minutes reaction time